Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 266 participants.

Also called NCT01663233

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 266 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01663233
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Japan, Malaysia, Philippines, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01663233. Randomized; triple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2015-08-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
Condition
Essential Hypertension
Intervention (Drug)
LCZ696
Intervention (Drug)
Amlodipine
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01663233
Content hash
608af3941540551018a01cbe2306e91465f984040585e3f75e6e81e73ab38824